Although currently approved NAs cannot alone achieve a functional cure, the chances of achieving a long-lasting functional cure for hepatitis B, with no rebound after stopping therapy, would be higher using a combination of immunomodulators, such as IFN-α and two or more antivirals that can target different steps in the virus replication cycle. This evidence concerns the gene IFNA1 and hepatitis B virus infection.